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LABORATORY INVESTIGATION
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The effects of daily cyclophosphamide administration on the develop-
ment and extent of primary experimental interstitial nephritis in rats. We
examined the effects of daily cyclophosphamide administration on the
development and extent of tubulointerstitial nephritis produced in rats
injected with tubular basement membranes in adjuvant. 15 mglkglday of
cyclophophamide completely blocked the development of interstitial
lesions, while 2 mg/kg/day enhanced the degree of interstitial injury.
When cyclophosphamide in the higher dose was started early in
disease, 12 days after immunization, protection from progression was
also observed as well as significant reductive improvement. If cyclo-
phosphamide was administered late in disease, 21 days after immuni-
zation, no further progression was demonstrable, but substantial injury
remained. In the latter two experiments, the beneficial effects of
cyclophosphamide could not be explained by a reduction in anti-tubular
basement membrane antibodies bound to the kidney. In groups of
immunized rats that were tested, however, cyclophosphamide was able
to non-specifically impair the delayed-type hypersensitivity response to
tubular antigen and PPD. We conclude, therefore, that cyclophospha-
mide, in high but not low dosage, if given before damage is extensive
and prolonged, may successfully inhibit the cellular immune response
producing primary interstitial nephritis.
Brown Norway rats immunized with renal tubular basement
membranes in adjuvant develop severe tubulointerstitial
nephritis [1, 21. The expression of disease is characterized by
the appearance of anti-tubular basement membrane antibodies
(aTBM-Ab) after 7 to 10 days followed by an intense mononu-
clear cell infiltrate within several weeks. The cellular lesions are
composed of T lymphocytes, macrophages, and Ig cells [31.
Because this autoimmune process is a standard and reproduc-
ible model of experimental interstitial nephritis, we chose to
utilize it in an analysis of the effects of cyclophosphamide on
the generation and progression of primary interstitial renal
lesions. Cyclophosphamide has been previously shown to have
a modulating influence both on the pathogenesis of spontaneous
glomerulonephritis [4, 5] and the interstitial disease associated
with progressive glomerular damage [61, and is frequently used
as an immunosuppressive agent in other clinical settings [7]
Received for publication March 4, 1985,
and in revised form July 11, 1985
© 1986 by the International Society of Nephrology
because of its alkylating action on DNA in rapidly proliferating
cells [8—10]. The treatment of interstitial nephritis in humans, on
occasion, has also included the use of cyclophosphamide [11].
The experimental or clinical efficacy of this drug, however, has
not been evaluated in the setting of primary interstitial renal
disease.
Methods
Animals. Female Brown Norway rats, weighing 100 to 120
grams, were obtained from the Charles River Breeding Labo-
ratories (Wilmington, Massachusetts, USA). They were main-
tained by the Department of Laboratory and Animal Medicine,
University of Pennsylvania, School of Medicine.
Preparation of the antigen. Rabbit renal tubular basement
membrane antigen (RTA) and liver basement membrane antigen
were isolated by a differential seiving technique [1]. Highly
enriched basement membrane fragments were sonicated,
lyophilized, and stored at —70°C. Soluble renal tubular antigen
(SRTA) and soluble liver antigen (SLA) were made from these
lyophilized membranes using collagenase digestion [1, 2]. PPD
was obtained from Connaught Laboratories (Ontario, Canada).
Induction of disease. Groups of rats were immunized with 2
mg of RTA in complete Freund' s adjuvant (CFA) by footpad or
subcutaneous injection [1]. Control animals received CFA
alone.
Cyclophosphamide (CTX) administration. Cyclophospha-
mide (Cytoxan, Mead-Johnson, Evansville, Indiana, USA) was
freshly prepared in distilled water (0.5—5.0 mg/mi). The drug
was administered intraperitoneally within one hour of prepara-
tion (either 2 or 15 mg/kg/day). Three drug protocols were used
for analysis. In the first study cyclophosphamide was adminis-
tered from days ito 21 after immunization; in the second study
it was given from days 12 to 33, and; in the third study from
days 21 to 42. All animals were sacrificed either on days 21, 33,
or 42, respectively. Control animals received equal volumes of
distilled water in an identical fashion.
Assessment of renal disease. Kidney tissue was prepared for
immunofluorescent and light microscopy by standard methods
for this laboratory [121. Direct immunofluorescence of tubular
staining by aTBM-Ab was graded from 0 to 4 and expressed as
a mean SEM for each group [1, 12]. Kidneys fixed in 10%
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Table 1. Effect of daily cyclophosphamide administration on the development of aTBM disease
Group Immunization
CTXC
dose
Days of
treatment N
Bound"
aTBM-Ab
Histologica
severity
Serum'
creatinine
White blo
cell count,
od
XJO
A RTA/CFA — — 8 3.6 0,2 1.9 0.2 0.94 14.2
B RTA/CFA 15 mg/kg 1—21 5 0.0 0.0 0.0 0.0 0.67 2.3
C RTAJCFA 15 mg/kg
2 mg/kg
1
2—21
6 2.3 0.2 3.4 0.4* 1.18 4.0
D RTA/CFA 2 mg/kg 1—21 5 2.8 0.5 2.5 0.5 1.15 4.7
E CFA 15 mg/kg 1—21 4 0.0 0.0 0.0 0.0 0.78 1.6
F CFA — — 4 0.0 0.0 0.0 0.0 0.65 9.3
a All control groups were injected with 0.5 cc H20/day during the treatment time in which the animals in the same experiment received their
cyclophosphamide (CTX).
b Intensity of direct immunofluorescence reported as mean SEM.
Graded histologic sections reported as the mean SEM.
d Creatinines reported as mean mg %.
Reported as cells/cubic mm.
* P < 0.003 compared to RTAICFA group (A).
formalin were stained with hematoxylin and eosin. Coded
multiple, complete longitudinal sections were examined by a
blinded observer and graded (mean SEM) according to the
extent of involved cortex on a scale of 0 to 4 [121: 0 = normal;
0.5 = small focal areas of cellular infiltration, 1 = cellular
infiltration and tubular damage involving less than 10% of the
cortex; 2 = involvement up to 25% of the cortex; 3 = involve-
ment up to 50 to 75% of the cortex, and; 4 = extensive damage
involving more than 75% of the cortex. The presence of
aTBM—Ab in serum was determined by solid-phase radio-
immunoassay [11. Pooled serum creatinines were measured
using the modified methods of Jaffe [13].
Induction and elicitation of a delayed-type hypersensitivity
(DTH) response to tubular antigen. Subcutaneously immunized
rats, in selected experiments, were challenged in the footpad
with 50 g of soluble antigen (SRTA, PPD, or SLA) in 50 .d of
PBS [2, 14]. 24 hours later, just prior to sacrifice, footpad
swelling as an index of DTH was measured using a spring-
loaded engineer's micrometer (Schlesinger's for Tools, Ltd.
Brooklyn, New York, USA). The magnitude of swelling was
expressed as the mean increment between antigen challenged
and the pre-challenged footpad in inches x l0 SEM. All
measurements were cage-blind.
White blood cell (WBC) counts. Heparinized whole blood
was diluted in red cell lysing solution and counted on a Coulter
counter (Coulter Electronics, Hialeah, Florida, USA).
Statistical analysis. Differences between experimental
groups were determined by Students' T test.
Results
Effects of daily cyclophosphamide administration on the
development of disease. In the first series of experiments we
examined the effects of daily cyclophosphamide administration
from the time of immunization, at different doses, on the
development of histologic tubulointerstitial disease (Table 1).
Six groups were sacrificed and studied on day 21. Groups A
through D were immunized with RTA in CFA. Group A was not
treated with cyclophosphamide and served as the positive
disease control. Groups B, C, and D received different dosing
schedules of cyclophosphamide, and groups E and F were
immunized with only CFA to provide non-disease controls.
Rats in Group B receiving a high, but tolerable dose of
Serum dilutions of anti-TBM antibody
Fig. 1. Serum aTBM-Ab titers following immunization. Serial dilutions
of immune serum were titered against solubilized tubular antigen by
radioimmunoassay 11]. Duplicates did not deviate by more than 5—7%.
A) aTBM-Ab titers from rats reported in Table 1: (—S) RTAJCFA;(*_*) CFA: (•----I) RTA/CFA + 15 mg/kg/day CTX; (U----)
RTA/CFA + 2 mg/kg/day CTX; (A----A) RTA/CFA + 15 mg/kg/day CTX
(day 1) and 2 mg/kg/day CTX (days 2 to 21). B) aTBM-Ab titers from rats
reported in Table 2: ( •) RTA/CFA (day 33); (•—U) RTAJCFA
(day 12); (A----A) RTA/CFA + 15mg/kg/day CTX (day 33); (*__*) CFA.
C) aTBM-Ab titers from rats reported in Table 4. (• •) RTAJCFA
(day 42); (U—•) RTAJCFA (day 21); (A----A) RTAICFA + 15
mg/kg/day (day 42);(*_*) CFA.
cyclophosphamide (15 mg/kglday), did not develop histologic
lesions or aTBM-Ab when compared to positive controls
(Group A). Fluorescent staining for aTBM-Ab was confined to
the tubular basement membranes of the renal cortex. Previous
double-label tracking studies have shown these antibodies
principally bind to proximal tubules, The serum creatinine
values from Group B were also similar to the negative controls
(Groups E and F). It should be recognized, however, that
glomerular filtration rate, serum creatinine, and renal plasma
flow all vary independently with weight, age, and dietary
intake. Evidence of a cyclophosphamide effect on the bone
marrow was demonstrated by a well tolerated, but marked
reduction in the WBC count. Rats receiving a lower dose of
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Fig. 2. Representative interstitial lesions. All lesions were confined to the renal cortex. A Area of infiltration taken from a kidney with focal areas
of involvement (0.5). B Cortical interstitial lesions with complete obliteration of the renal architecture taken from a kidney with diffuse involvement
(4.0). x120
cyclophosphamide at 2 mg/kg/day (Group D), or 15 mg/kg on
day 1, and 2 mg/kg/day thereafter (Group C), demonstrated
substantial amounts of kidney-bound rTBM-Ab, and only
slightly reduced aTBM-Ab titers by radioimmunoassay (see
Figure 1A) compared to Group A. Both Groups C and D,
however, developed more histologic disease (Group D just miss-
mg statistical significance; P < 0.06). The changes in serum
creatinines in both of these latter groups tended to be higher,
paralleling the histologic evidence of more severe disease. The
histologic lesions produced in these Brown Norway rats were
similar to those previously reported [15, 16]. The disease was
confined to the renal cortex, and began as focal cellular infiltrates
which gradually became diffuse, producing tubular diitation and
disruption of the tubular architecture. The glomeruli were not
involved, and remained normal in appearance until they were
trapped within an enlarging interstitial inifitrate (Fig. 2).
Effects of daily cyclophosphamide administration beginning
early (12 days) after immunization to produce disease. Four
groups were studied to evaluate the effects of cyclophospha-
mide on early, established interstitial disease. Non-drug treated
rats immunized with RTA and CFA were sacrificed on days 12
and 33. Another group received 15 mg/kg of cyclophosphamide
from days 12 to 33, and a fourth group immunized with CFA
served as a negative control. By 12 days after immunization
with RTA/CFA, the time-control rats had already developed
early but substantial interstitial lesions (Table 2). Untreated, the
degree of interstitial damage progressed by day 33 and was
associated with a persistently elevated serum creatinine. The
group receiving 15 mg/kg/day of cyclophosphamide beginning
on day 12 did not progress and, in fact, had a slightly reduced
mean histologic score when compared to the rats sacrificed on
day 12. Cyclophosphamide treatment also had a protective
effect on the serum creatinine. The cyclophosphamide treat-
ment, however, did not alter the amount of aTBM-Ab bound
along the tubular basement membrane, but did affect the overall
level of serum aTBM-Ab by day 33 (Fig. lB).
Since the cyclophosphamide treatment beginning on day 12
had a pronounced effect on bone marrow production of WBC's
(Table 2), we were interested in determining its impact on the
effector cell-mediated immune response to tubular antigen. We
have previously demonstrated that the delayed-type hypersen-
sitivity (DTH) response to tubular antigen is a T cell-dependent
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Table 2. Effect of daily cyclophosphamide administration early in the course of aTBM disease
Immuni-
zation
CTX
dose
Days of
treatment
Sacrifice
day N
Bound5
aTBM-Ab
Histologicale
severity
Serumd
creatinine
White blo
cell count,
ode
)<
RTAJCFA — — 33 7 3.3 0.3 2.9 0.3 1.32 13.3
RTA/CFA — — 12 7 3.3 0.5 1.5 0.4* 1.15 20.6
RTA/CFA 15 mg/kg 12—33 33 7 3.5 0.5 1.0 0.2* 0.92 1.2
CFA — — 33 4 0.0 0.0 0.0 0.0 0,86 9.3
* All control groups were injected with 0.5 cc H20/day during the treatment time in which the animals in the same experiment received their
cyclophosphamide (CTX).
Intensity of direct immunofluorescence reported as mean 5EM.
Graded histologic sections reported as the mean SEM.
ci Creatinines reported as mean mg %.
Reported as cells/cubic mm.
* P c 0.001 compared to RTA/CFA group on day 33.
Table 3. Delayed-type hypersensitivity response to tubular antigen
Group DTH Response5
Immunization Treatmenta SRTA PPD SLA
RTA/CFA — 17.3 2.0* 20.6 0.9* 4.3 0.7
RTA/CFA CTX 5.2 1.0 4.5 0.5 —
CFA — 3.8 0.6 22.0 0.7*
— — 4.2±0.7 5.0±0.4 5.0±0.4
Cyclophosphamide (CTX; 15 mg/kg/day) was administered from
days 12 to 33. All control groups were injected with 0.5 cc H20/day
during the treatment time in which the animals in the same experiment
received their CTX.
Data points from 4 to 6 rats per measurement were calculated as the
mean increment inches x l0 5EM, 33 days alter immunization, 24
hours after challenge with antigen.
* P c 0.001 compared to unimmunized controls.
and antigen-specific measure of nephritogenic potential [2]. In
Table 3, DTH responses were measured in rats followed to day
33. The results indicate that rats treated from days 12 to 33 with
15 mg/kg/day of cyclophosphamide developed a non-specific
and severe impairment of DTR, as the response to both SRTA
and PPD were reduced.
Effects of daily cyclophosphamide administration beginning
late (21 days) after immunization to produce disease. In this last
group of experiments, rats were treated with 15 mg/kg/day of
cyclophosphamide from days 21 to 42 (Table 4), and compared
to non-treated controls immunized with RTA and CFA and
sacrificed at days 21 and 42. The time-control group sacrificed
on day 21 revealed significant interstitial damage. Rats followed
to day 42 demonstrated a progression of histologic disease
which was not observed in the group receiving cyclophospha-
mide (P c 0.01). All rats immunized with RTA/CFA showed
significant kidney-bound aTBM-Ab, and the serum aTBM-Ab
titer of the group receiving cyclophosphamide did not increase
beyond that observed in rats sacrificed on day 21 (Fig. 1C). A
significant effect of cyclophosphamide was again demonstrated
on the WBC count (Tahle 4).
Discussion
The findings in the present study indicate that cyclophospha-
mide at 15 mg/kg/day is well tolerated in the rat, and can
effectively and completely prevent the development of primary
interstitial renal lesions when given at the time of immunization.
This observation is consistent with previous findings that one
large dose of cyclophosphamide (200 mg/kg) within 72 hours of
immunization can inhibit the development of interstitial disease
in guinea pigs [17]. If cyclophosphamide is used early after
disease is present, we also noted that it can retard the progres-
sion of renal damage. Even if cyclophosphamide is adminis-
tered late in the disease there still is a reduction in progression,
although considerable interstitial injury remains. The use of
lower doses of cyclophosphamide (2 mg/kg/day), however,
resulted in more severe lesions at 21 days (Table 1). Such a
seemingly parodoxical finding can be explained by previous
observations that low-dose cyclophosphamide can eliminate
either non-specific suppressor cells [2] or autologous cell-
mediated tolerance (C. Kelly; manuscript in preparation) which
results in more severe cellular interstitial injury. In some
experimental systems low-dose cyclophosphamide also seems
to preferentially inhibit suppressor T cells when compared to
the helper cell subpopulation [18, 19].
The mechanism of the protective effect at a dose of 15
mg/kg/day appears to be principally directed towards the cellu-
lar immune response; that is, when cyclophosphamide was
begun at the time of immunization, neither a B cell response nor
a mixed cellular lesion ever evolved. When cyclophosphamide
was started 12 days after immunization, however, significant
amounts of aTBM-Ab were present, but the cell-mediated
effector response, reflected in a delayed-type hypersensitivity
reaction, was non-specifically impaired. This lack of cyclophos-
phamide effect on previously established antibody responses
has also been observed in other experimental systems [20]. It is
also unlikely that the reduction in cell-mediated immunity was
due to the induction of a non-specific suppressor cell mecha-
nism, as such suppressor cells usually are cyclophosphamide-
sensitive [2].
The current observations from our work are also supported
by previous findings where cyclophosphamide was used to treat
interstitial nephritis associated with autoimmune glomerulone-
phritis in mice [6]. The daily dose of 15 mg/kg/day was chosen
for the present studies because it has been previously shown
that mice can tolerate such a treatment regimen without notice-
able side effects [4-6]. The BN rat also can tolerate this dose
schedule, and no animals were lost in any of the treatment
groups during the course of our study. It appears, in fact, that
noticeable increases in mortality from the drug are only mani-
fest after doses of 20 mg/kg/day [21]. A direct dose comparison
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Table 4. Effect of daily cyclophosphamide administration late in the course of aTBM disease
Immuni-
zation
CTXa
dose
Days of
treatment
Sacrifice
day N
Bound"
aTBM-Ab
Histologicale
severity
Serum
creatinine
White blo
cell count,
ode
X103
RTA/CFA — — 42 8 4.0 0.0 2.8 0.4 1.26 11.1
RTAJCFA — — 21 8 3.6 0.2 1.9 0.2 0.94 14.2
RTA/CFA 15 mg/kg 21—42 42 6 3.3 0.5 2.2 0.3* 1.07 1.9
CFA — — 42 4 0.0 0.0 0.0 0.0 0.87 8.6
a All control groups were injected with 0.5 cc H20/day during the treatment time in which the animals in the same experiment received their
cyclophosphamide (CTX).b Intensity of direct immunofluorescence reported as mean SEM.
Graded histologic sections reported as the mean SEM.d Creatinines reported as mean mg %.
Reported as cells/cubic mm.
* P < 0.01 compared to RTAJCFA group on day 42.
with man, however, is not really possible, as all metabolites of
cyclophosphamide have not been formally measured on a
kinetic basis in rats. Overall alkylating activity, which bears a
relationship to levels of metabolites, has nevertheless been
determined in both species [22]. While peak alkylating activity
in man is 50—75% of that in the rat, the elimination constant in
man is only 66% of that in the rat. Furthermore, although the
kinetics of metabolite blood levels are important for the
cytostatic effect of cyclophosphamide [23], other unknown
bone marrow factors in rats may contribute to the tolerance of
the drug during long-term usage, as most humans do not
tolerate 15 mg/kg/day of cyclophosphamide.
In summary, our data suggest that cyclophosphamide can be
used to modify the expression of interstitial nephritis, Our
findings also suggest that the earlier it is used, the better the
protective effect, and that higher doses are required as opposed
to lower doses which may actually potentiate the expression of
disease. Whether this protection extends beyond the time when
cyclophosphamide is discontinued remains to be determined.
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